CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma

CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma

Abstract BRD4 is a member of the BET protein family involved in chromatin remodeling and transcriptional regulation. Several BET inhibitors (BETi) have entered clinical trials, demonstrating potential in inducing cancer cell apoptosis and tumor regression. However, resistance to BETi is common in so...

Full description

Bibliographic Details
Main Authors:	Yin Zhang, Ranran Yu, Cheng Zhao, Jiawei Liang, Yixuan Zhang, Haochen Su, Jing Zhao, Hao Wu, Shijin Xu, Ziying Zhang, Lei Wang, Xiaoping Zou, Yun Zhu, Shu Zhang, Ying Lv
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	Advanced Science
Subjects:	cancer‐associated fibroblasts nano delivery system pancreatic cancer tumor microenvironment
Online Access:	https://doi.org/10.1002/advs.202305279

Similar Items

Pirfenidone inhibits stromal collagen deposition and improves intra-tumoral delivery and antitumor efficacy of Pegylated liposomal doxorubicin
by: Tiantian Cai, et al.
Published: (2023-01-01)

Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer
by: Xinglong Geng, et al.
Published: (2021-07-01)

Irinotecan/scFv co-loaded liposomes coaction on tumor cells and CAFs for enhanced colorectal cancer therapy
by: Zhaohuan Li, et al.
Published: (2021-12-01)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
by: Wan Qin, et al.
Published: (2020-01-01)

Pirfenidone Reduces Epithelial–Mesenchymal Transition and Spheroid Formation in Breast Carcinoma through Targeting Cancer-Associated Fibroblasts (CAFs)
by: Hamidreza Aboulkheyr Es, et al.
Published: (2021-10-01)

Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment
by: Vineela Parvathaneni, et al.
Published: (2020-02-01)

Characterization of cancer-associated fibroblasts (CAFs) and development of a CAF-based risk model for triple-negative breast cancer
by: Ganggang Wang, et al.
Published: (2023-11-01)

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan
by: Kenneth H. Yu, et al.
Published: (2021-07-01)

Design and applications of liposome-in-gel as carriers for cancer therapy
by: Yixuan Mou, et al.
Published: (2022-12-01)

The role of BET attenuation in melanoma
by: Henderson, EK
Published: (2020)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
by: Alberto Juan, et al.
Published: (2022-09-01)

Targeted drug delivery systems for pancreatic ductal adenocarcinoma: overcoming tumor microenvironment challenges with CAF-specific nanoparticles
by: Xinming Su, et al.
Published: (2023-12-01)

Advances in Antitumor Effects Using Liposomal Citrinin in Induced Breast Cancer Model
by: Michely Laiany Vieira Moura, et al.
Published: (2024-01-01)

A Proteomic Study on the Personalized Protein Corona of Liposomes. Relevance for Early Diagnosis of Pancreatic DUCTAL Adenocarcinoma and Biomarker Detection
by: Luca Digiacomo, et al.
Published: (2021-06-01)

Biomimetic liposomal nanozymes improve breast cancer chemotherapy with enhanced penetration and alleviated hypoxia
by: Juanjuan Li, et al.
Published: (2023-04-01)

Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterization, and Evaluation
by: Adam Markowski, et al.
Published: (2023-01-01)

Preparation of DSPE-PEG-cRGD Modified Cationic Liposomes for Delivery of OC-2 shRNA and The Antitumor Effects on Breast Cancer
by: Chunyan Liu, et al.
Published: (2022-10-01)

CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?
by: Chunxue Zhang, et al.
Published: (2023-03-01)

Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma
by: Xiaomeng Liu, et al.
Published: (2023-01-01)

High expressions of CD10, FAP and GPR77 in CAFs are associated with chemoresistance and worse prognosis in gastric cancer
by: Yilin Tong, et al.
Published: (2022-10-01)

Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation
by: Meng H, et al.
Published: (2015-06-01)

Integrins, CAFs and Mechanical Forces in the Progression of Cancer
by: Imjoo Jang, et al.
Published: (2019-05-01)

Biomimetic Boron Nitride Nanoparticles for Targeted Drug Delivery and Enhanced Antitumor Activity
by: Hui Li, et al.
Published: (2023-04-01)

Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC
by: Kong L, et al.
Published: (2020-08-01)

Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
by: Li Tian, et al.
Published: (2018-01-01)

Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma
by: Justyna Budka, et al.
Published: (2024-02-01)

A Quick Guide to CAF Subtypes in Pancreatic Cancer
by: Anna Brichkina, et al.
Published: (2023-05-01)

Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC [Corrigendum]
by: Kong L, et al.
Published: (2021-12-01)

Cholesterol Significantly Affects the Interactions between Pirfenidone and DPPC Liposomes: Spectroscopic Studies
by: Irina M. Le-Deygen, et al.
Published: (2022-02-01)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
by: Sebastian Marwitz, et al.
Published: (2020-01-01)

Ligand-modified homologous targeted cancer cell membrane biomimetic nanostructured lipid carriers for glioma therapy
by: Mengyu Chen, et al.
Published: (2021-01-01)

Breast Cancer CAFs: Spectrum of Phenotypes and Promising Targeting Avenues
by: Eiman Elwakeel, et al.
Published: (2021-10-01)

Secretome of Stromal Cancer-Associated Fibroblasts (CAFs): Relevance in Cancer
by: Deepshikha Mishra, et al.
Published: (2023-02-01)

Exosomes-mediated transfer of LINC00691 regulates the formation of CAFs and promotes the progression of gastric cancer
by: Bin Xia, et al.
Published: (2023-10-01)

CD146+CAFs promote progression of endometrial cancer by inducing angiogenesis and vasculogenic mimicry via IL-10/JAK1/STAT3 pathway
by: Zhicheng Yu, et al.
Published: (2024-03-01)

Review: Challenges of In Vitro CAF Modelling in Liver Cancers
by: Alba Herrero, et al.
Published: (2021-11-01)

Fight the Cancer, Hit the CAF!
by: Andrea Papait, et al.
Published: (2022-07-01)

Role of BET Inhibitors in Triple Negative Breast Cancers
by: Durga Khandekar, et al.
Published: (2020-03-01)

Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity
by: Han B, et al.
Published: (2020-01-01)

Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor
by: Pang N, et al.
Published: (2018-10-01)